Rotavirus vaccines--an update.
Rotavirus vaccines offer the best hope to reduce the toll of acute rotaviral gastroenteritis in both developed and developing countries. An association with intussusception (IS) led to the withdrawal of the first licensed rotavirus vaccine in the USA in 1999, forcing a re-evaluation of the safety profile of potentially lifesaving vaccines. Development of new rotavirus vaccine candidates has continued, with a bovine-human reassortant vaccine and an attenuated human monovalent vaccine commencing Phase III trials. Several other candidates are in early Phase I and II clinical trials. The creation of innovative funding strategies to support vaccine development and production, specifically in developing countries, aim to make vaccines available where rotavirus causes the greatest impact.
Kirkwood
Carl D
CD
Department of Gastroenterology and Clinical Nutrition, Murdoch Childrens Research Institute, Royal Children's Hospital, Flemington Road, Parkville, Victoria, Australia, 3052. kirkwooc@cryptic.rch.unimelb.edu.au
Buttery
Jim
J
D000818:Animals; D017321:Clinical Trials, Phase I as Topic / Q000639:trends; D017322:Clinical Trials, Phase II as Topic / Q000639:trends; D006801:Humans; D012400:Rotavirus Infections / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control*; D022243:Rotavirus Vaccines / Q000276:immunology / Q000627:therapeutic use*
D022243:Rotavirus Vaccines